Biocollection for patients with Myelodysplastic Syndromes
Biocollection in Patients With Myelodysplastic Syndrome (P-MDS)
NA · University Hospital, Brest · NCT04869683
This study is collecting samples from patients with Myelodysplastic Syndromes to help researchers learn more about how certain gene mutations affect blood cell development.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Brest (other) |
| Locations | 1 site (Brest) |
| Trial ID | NCT04869683 on ClinicalTrials.gov |
What this trial studies
This study aims to collect biological samples from patients diagnosed with Myelodysplastic Syndromes (MDS) to support three scientific projects focused on understanding the disease's pathophysiology. One of the key projects investigates splicing anomalies in MDS patients with SF3B1 mutations, which are prevalent in this population. By analyzing RNA sequences, researchers hope to uncover the functional implications of these mutations and their role in the formation of specific blood cell types. The study will involve patients managed at the Cancer-Hematology Institute of the Brest CHRU.
Who should consider this trial
Good fit: Ideal candidates include adults diagnosed with or suspected of having Myelodysplastic Syndromes who are receiving care at the Cancer-Hematology Institute of the Brest CHRU.
Not a fit: Patients who are minors, pregnant, or unable to provide consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this research could lead to a better understanding of MDS and improved treatment strategies for patients.
How similar studies have performed: While the specific approach of this biocollection is novel, similar studies investigating genetic mutations in MDS have shown promise in advancing understanding of the disease.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Major * patient with or suspected of myelodysplastic syndrome (WHO definition) at diagnosis and/or during follow-up, which is managed at the level of the Cancer-Hematology Institute of the Brest CHRU * Presence of biological material collected within the CRB * Patient's consent obtained Exclusion Criteria : * Minor and pregnant woman * Lack of biological material collected within the CRB * Refusal to participate: lack of consent - Unable to consent * Patient under judicial protection: guardianship, curatorship ...
Where this trial is running
Brest
- Chu Brest — Brest, France (RECRUITING)
Study contacts
- Principal investigator: Nathalie Douet-Guilbert, MD,PhD — CHRU BREST
- Study coordinator: Nathalie Douet-Guilbert, MD, PhD
- Email: nathalie.douet-guilbert@chu-brest.fr
- Phone: +33229020215
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Myelodysplastic Syndromes, Myelodysplastic Anemia, Myelodysplastic Syndrome With Isolated Del, Myelodysplastic Syndrome With Ring Sideroblasts, Acute Myeloid Leukemia With Multilineage Dysplasia, Chromosome Abnormality, MDS, 5q deletion